VTP 38543

Drug Profile

VTP 38543

Alternative Names: VTP-38543

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Vitae Pharmaceuticals
  • Developer Allergan
  • Class Small molecules
  • Mechanism of Action Liver X receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Atopic dermatitis

Most Recent Events

  • 14 Sep 2016 Allergan enters into a definitive merger agreement with Vitae Pharmaceuticals
  • 01 Sep 2016 Vitae Pharmaceuticals completes a phase II trial in Atopic dermatitis in USA and Canada (NCT02655679)
  • 10 Dec 2015 Phase-II clinical trials in Atopic dermatitis in Canada after December 2015 (Topical) (NCT02655679)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top